Amounts in thousands of United States dollars
September 30, September 30,
2024 2023
------------------------------------------- --------------- ---------------
Cash $ 103,710 $ 33,702
Prepaids and other assets 24,402 115,420
--------------- ---------------
Total assets $ 128,112 $ 149,122
Current liabilities 3,301 3,495
Long-term lease liability 205 -
Shareholders' deficiency 124,606 145,627
--------------- ---------------
Total liabilities and shareholders' equity $ 128,112 $ 149,122
=========================================== =============== ===============
ESSA PHARMA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Amounts in thousands of United States dollars, except share and per share data
Three months Three months
ended ended Year ended Year ended
September 30, September 30, September 30, September 30,
2024 2023 2024 2023
------------------ --------------------- ------------------- ------------------- -------------------
OPERATING EXPENSES
Research and
development $ 4,188 $ 5,226 $ 21,207 $ 21,323
Financing costs - 1 - 7
General and
administration 3,507 1,922 13,214 10,812
--------------------- ------------------- ------------------- -------------------
Total operating
expenses (7,695) (7,149) (34,421) (32,142)
--------------------- ------------------- ------------------- -------------------
Interest and
other items 1,339 1,668 5,878 5,560
--------------------- ------------------- ------------------- -------------------
Net loss before
taxes (6,356) (5,481) (28,543) (26,582)
Income tax expense
(recovery) -- -- - (2)
--------------------- ------------------- ------------------- -------------------
Net loss for the
period $ (6,356) $ (5,483) $ (28,543) $ (26,584)
OTHER
COMPREHENSIVE
LOSS
Unrealized gain
(loss) on short-
term investments 37 2 57 15
--------------------- ------------------- ------------------- -------------------
Loss and
comprehensive
loss for the
period $ (6,319) $ (5,479) $ (28,486) $ (26,569)
Basic and diluted
loss per common
share $ (0.14) $ (0.12) $ (0.64) $ (0.60)
================== ===================== =================== =================== ===================
Weighted average
number of common
shares
outstanding 44,366,126 44,092,374 44,277,050 44,089,557
================== ===================== =================== =================== ===================
View original content:https://www.prnewswire.com/news-releases/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-fourth-quarter-and-year-ended-september-30-2024-302333326.html
SOURCE ESSA Pharma Inc
(END) Dow Jones Newswires
December 17, 2024 07:00 ET (12:00 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。